Intensity Therapeutics (INTS) Stock
Early stage biotech developing cancer drug delivery methods. Here's the price, business snapshot, and what's worth knowing about Intensity Therapeutics in October 2026.
Intensity Therapeutics Inc (INTS) is a very small‑cap, clinical‑stage biopharmaceutical company focused on oncology-related drug delivery and immunotherapy approaches. With a market capitalisation of roughly $12.6m, the company is speculative and typically of interest to investors who follow early‑stage biotech. Key investor considerations include the development pipeline, upcoming clinical readouts or partnership announcements that can materially affect the share price, and the company’s cash position and ability to finance operations. As with most micro‑cap biotech names, shares can be highly volatile, thinly traded and susceptible to dilution if additional capital is required. Potential rewards — if clinical or regulatory milestones succeed — come with commensurate risks, including clinical failure, regulatory setbacks and financing risk. This summary is general educational information only and not personal investment advice; suitability depends on your risk tolerance and financial situation.
Intensity Therapeutics (INTS) Stock Forecast
Analyst price target, next 12 months
$14.07
+313.9% vs today's $3.40
Price range over the last 12 months
Close to its 12-month low
Analysts covering Intensity Therapeutics have a consensus 12-month target of $14.07, above the current price of $3.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intensity Therapeutics' stock with a target price of $14.07, indicating strong growth potential.
Financial Health
Intensity Therapeutics is doing well with healthy cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform technology potential
The company’s delivery‑focused platform is positioned to enhance oncology treatments if validated, though clinical proof is uncertain and outcomes may vary.
Clinical catalysts ahead
Trial readouts, partnerships or regulatory news can sharply move the share price; these events are binary and can lead to sizeable gains or losses.
Small‑cap considerations
A market cap around $12.6m implies limited liquidity and financing risk; investors should expect potential dilution and pronounced volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
